

REMARKS

Claims 2, 3, 6, 8-11, 13, 16, 17 and 19 are pending the application; Claims 2, 3, 6, 8-11, 13, 16, 17 and 19 stand rejected. By this Amendment Claims 8, 16, 17 and 19 have been amended. These amendments add no new matter to the application.

Claims 2, 6, 8, 9, 13, 16, 17 and 19 are rejected under 35 USC 102(a) as allegedly anticipated by Womack; Applicants respectfully traverse these rejections. Claims 8 and 17 have been amended to recite a combination of *Uncaria tomentosa* and Ginkgo Biloba, in further combination with one or more of a list of other ingredients. Womack neither teaches nor suggests the efficacy of combining Ginkgo with *Uncaria tomentosa*, and adding to that combination any other ingredients. Claims 8 and 17 are therefore not anticipated by Womack, and reconsideration of these claims is requested.

Claims 16 and 19 have been amended to recite a combination of *Uncaria tomentosa* and then one or more substances from a group including Bilberry, Dong Quai and Aloe Vera, in further combination with one or more of a list of other ingredients. Womack neither teaches nor suggests the efficacy of combining *Uncaria tomentosa* with either Bilberry, Dong Quai or Aloe Vera, and adding to that combination any other ingredients. Claims 16 and 19 are therefore not anticipated by Womack, and reconsideration of these claims is requested as well. All other claims depend from one of these four amended claims, and as such all contain the amended limitations as well, and are therefore also not anticipated.

Claims 2, 3, 6, 8-11 and 17 are rejected under 35 USC 103(a) over Womack; Applicants respectfully traverse these rejections. Because amended claims 8, 16, 17 and 19 now recite combinations neither taught nor suggested by Womack, as discussed above, all of these claims and their dependents are now distinguished over Womack and are believed to be in condition for allowance. Reconsideration is requested.

The double patenting rejection of Claims 2, 3, 6 and 17 is now believed to be moot in view of the amendment of claim 17 to delete Gotu Kola, the only ingredient formerly common to both the cited patent and the instant claims.

It is believed that the amendments to Claims 8, 16, 17 and 19 render moot the Examiner's objection under 37 CFR 1.75, as the amended claims are not substantial duplicates of one another.

Applicant believes that he has responded fully to all of the concerns expressed by the Examiner in the Office Action, and respectfully requests that new Claims be entered and examined, and that early favorable action be taken on all claims pending in the application. Applicant respectfully requests reexamination of all rejected claims and early favorable action on them as well. If the Examiner has any further concerns, Applicant requests a call to Applicant's attorney Patrick Dwyer at (206) 343-7074.

Respectfully submitted,



PATRICK MICHAEL DWYER
Reg. No. 32,411

P07CI3-OA2.RSP

PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109

Amended Claims
(Version with Markings to Show Changes Made)

8. A method of treating an amyloid disease in a patient, comprising the step of administering to the patient a therapeutically effective amount of a combination of Gingko Biloba and plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of ~~Gingko Biloba~~, Ginseng, ~~Gotu Kola~~, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12 or cobalamin, and Choline.

16. A method of treating an amyloid disease in a patient, comprising the step of administering to the patient a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Bilberry, Dong Quai; and Aloe Vera, and a therapeutically effective amount of one or more substances selected from the group consisting of Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1.

17. A pharmacological agent comprising a therapeutically effective amount of a combination of Gingko Biloba and plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of ~~Gingko Biloba~~, Ginseng, ~~Gotu Kola~~, Echinacea, Vitamin E, Selenium, Niacin or nicotinate, Folic acid, Vitamin B12, and Choline, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in treating an amyloid disease in a patient.

19. A pharmacological agent comprising a therapeutically effective amount of plant matter from a plant of the genus *Uncaria*, species *tomentosa*, in combination with a therapeutically effective amount of one or more substances selected from the group consisting of Dong Quai,

Bilberry and Aloe Vera, and a therapeutically effective amount of one or more substances selected from the group consisting of Chromium Polynicotinate, Selenium, Vitamin B12 or cobalamin, Folic acid, Biotin, and Thiamine HCl, or vitamin B1, the plant matter and substance and the therapeutic amount of the plant matter and substance selected for efficacy in treating an amyloid disease in a patient.